New drug ALK-N001 targets advanced solid tumors in early trial
Disease control
Not yet recruiting
This study tests an injectable drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing, and to check its safety. The trial is in early phases (Ib and I…
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 03, 2026 21:16 UTC